ImmunityBio (NASDAQ:IBRX) Shares Down 10%

ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating)’s share price was down 10% on Thursday . The stock traded as low as $2.89 and last traded at $2.89. Approximately 34,185 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 1,729,344 shares. The stock had previously closed at $3.21.

Separately, Piper Sandler reduced their target price on ImmunityBio from $20.00 to $10.00 in a report on Friday, May 27th.

The company has a fifty day moving average price of $3.97 and a two-hundred day moving average price of $5.41.

Several institutional investors have recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of ImmunityBio by 8.8% in the 1st quarter. State Street Corp now owns 6,760,306 shares of the company’s stock valued at $37,925,000 after purchasing an additional 544,929 shares during the last quarter. Geode Capital Management LLC raised its stake in ImmunityBio by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,556,601 shares of the company’s stock valued at $9,464,000 after acquiring an additional 40,345 shares during the last quarter. JPMorgan Chase & Co. raised its stake in ImmunityBio by 6.3% during the 4th quarter. JPMorgan Chase & Co. now owns 1,271,192 shares of the company’s stock valued at $7,729,000 after acquiring an additional 75,883 shares during the last quarter. Rafferty Asset Management LLC raised its stake in ImmunityBio by 83.0% during the 4th quarter. Rafferty Asset Management LLC now owns 825,388 shares of the company’s stock valued at $5,018,000 after acquiring an additional 374,349 shares during the last quarter. Finally, Morgan Stanley raised its stake in ImmunityBio by 1.9% during the 3rd quarter. Morgan Stanley now owns 497,724 shares of the company’s stock valued at $4,849,000 after acquiring an additional 9,434 shares during the last quarter. 8.67% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile (NASDAQ:IBRX)

ImmunityBio, Inc, a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.

Featured Articles

• Get a free copy of the StockNews.com research report on ImmunityBio (IBRX)
• The Q2 Earnings Season Could Be A Bloodbath 
• Commercial Metals Company Is Ready To Rebound 
• The Institutions Turn The Tide For Jabil
• A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
• Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates

Want More Great Investing Ideas?